Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
- Astellas Shoots for Annual 8% Growth through FY2025: 5-Year Plan
May 27, 2021
- Daiichi Sankyo’s Humira Biosimilar Now Available in Japan
May 27, 2021
- Takeda Stepping Up Work to Improve Japanese Ecosystem for Rare Diseases
May 27, 2021
- Sawai, Towa Post Domestic Sales Growth in FY2020, but Nichi-Iko Falters on GMP Violations: Jiho Tally
May 26, 2021
- Nihon Generic Recalling Ursodeoxycholic Acid Drug over Human Hair Contamination
May 25, 2021
- Takeda’s Dengue Vaccine Shows Long-Term Efficacy
May 25, 2021
- Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
- Novartis Aims to Become Leader in Japan MS Market with Kesimpta Rollout
May 25, 2021
- Japan Ethical Drug Market Contracts 1% in Jan.-Mar.; Keytruda Top-Selling Drug for 8th Quarter Running: IQVIA
May 25, 2021
- Janssen Seeks Japan Approval for COVID-19 Vaccine
May 24, 2021
- Takeda’s CMV Drug Maribavir Gets FDA’s Priority Review
May 24, 2021
- Chugai’s FoundationOne Liquid Grabs Nod as Lynparza CDx
May 24, 2021
- AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
- Novo CEO Eyes 6-10% Annual Growth, Voices Hope for Rybelsus Tie-Up in Japan
May 20, 2021
- Third GPCR-Targeted Drug Enters Clinic under Sosei/Pfizer Collaboration
May 20, 2021
- Medicago’s COVID-19 Vaccine Yields Positive Interim Data: PII
May 20, 2021
- Life Science Institute to Establish New Field of Reparative Medicine with Muse Cells: President
May 20, 2021
- Janssen’s Darzquro, Chugai’s Polivy, JCR’s Izcargo Now Available in Japan
May 20, 2021
- Meiji Holdings Aims for 209 Billion Yen Pharma Sales in FY2023: New Biz Plan
May 20, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…